• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Hydroxychloroquine may have a treatment role for chronic inflammatory cardiomyopathy

byPaary BalakumarandAlex Chan
August 14, 2025
in Cardiology, Chronic Disease, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Hydroxychloroquine plus prednisolone reduced the 12-month risk of the composite cardiovascular outcome by 72 percent compared with prednisolone alone.

2. Hydroxychloroquine plus prednisolone normalized a wide range of inflammation-related proteins, indicating multiple anti-inflammatory effects.

3. The safety profile was similar to prednisolone alone, with no serious treatment-related adverse events.

Evidence Rating Level: 1 (Excellent)

In this multicenter, open-label, evaluator-blinded, randomized phase II trial (HYPIC), 50 adults with chronic inflammatory cardiomyopathy (infl-CMP) following fulminant myocarditis (FM) were randomized to receive either hydroxychloroquine (HCQ) plus prednisolone (PDN) or PDN alone for 12 months, in addition to guideline-directed heart failure therapy. The primary endpoint was a composite of cardiovascular death or heart transplant, hospitalization for heart failure or recurrent myocarditis, and permanent pacemaker or implantable cardioverter-defibrillator implantation. Secondary outcomes included changes in left ventricular ejection fraction (LVEF), left ventricular internal diastolic diameter (LVIDd), high-sensitivity cardiac troponin I (hs-cTnI), NT-proBNP, hs-CRP, and ESR. HCQ + PDN significantly reduced the primary composite outcome versus PDN alone (24.0% vs. 60.0%, HR 0.28, 95% CI 0.11–0.71) and led to greater improvements in LVEF, LVIDd, hs-cTnI, NT-proBNP, and hs-CRP (all p < 0.05). Proteomic analysis showed HCQ + PDN normalized 16 inflammatory proteins compared with only 2 in the PDN group. Adverse events were similar between groups, with no serious drug-related events. The authors conclude that HCQ + PDN for 12 months improves prognosis, cardiac function, and inflammation control in infl-CMP after FM, with acceptable safety, supporting further large-scale trials.

Click to read the study in BMC Medicine

RELATED REPORTS

Lifestyle factors including higher body mass index and smoking are associated with changes in left-atrial size and function

Artificial intelligence designed drugs Hit 90% Phase I success rate in trials

Sodium-glucose cotransporter 2 inhibitors may improve left ventricular diastolic function in hypertrophic cardiomyopathy

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: cardiologyCardiomyopathyhydroxychloroquinepharmacologyrheumatology
Previous Post

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

Next Post

FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis

RelatedReports

Cardiology

Lifestyle factors including higher body mass index and smoking are associated with changes in left-atrial size and function

March 3, 2026
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

Artificial intelligence designed drugs Hit 90% Phase I success rate in trials

February 19, 2026
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Sodium-glucose cotransporter 2 inhibitors may improve left ventricular diastolic function in hypertrophic cardiomyopathy

February 17, 2026
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026
Next Post
Tramadol use linked with increased risk of hypoglycemia hospitalizations

FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis

#VisualAbstract: Riociguat Improves Exercise Following Balloon Pulmonary Angioplasty in Patients with Pulmonary Hypertension

#VisualAbstract: Riociguat Improves Exercise Following Balloon Pulmonary Angioplasty in Patients with Pulmonary Hypertension

Parental nonmedical prescription opioid use linked to adolescent use

Medical cannabis has a high discontinuation rate for treatment of musculoskeletal pain

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher sleep apnea-specific hypoxic burden may predict postoperative cardiovascular complications and mortality in obstructive sleep apnea
  • Merck and Mayo Clinic launch AI-driven precision medicine lab
  • Lifestyle factors including higher body mass index and smoking are associated with changes in left-atrial size and function
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.